2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101863
    CB-6673567 379218-90-3 98%
    CB-6673567 is a selective AC1 inhibitor with an IC50 of 77 μM .CB-6673567blocks the choline-induced cAMP increase and can be used for cardiovascular diseases research.
    CB-6673567
  • HY-102054
    Acetylhydrolase-IN-1 79637-91-5 98%
    Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (Alkylacetyl-GPC: acetylhydrolase) inhibtor.
    Acetylhydrolase-IN-1
  • HY-10275A
    Atecegatran TFA 433937-75-8 98%
    Atecegatran TFA (AR-H067637 TFA) is an anticoagulant with selective direct thrombin inhibitory activity. Atecegatran TFA is commonly used to inhibit cardiovascular diseases. The biotransformation product of Atecegatran TFA, AR-H067637, is its active form and participates in the anticoagulation process.
    Atecegatran TFA
  • HY-10304A
    Orbofiban acetate 163250-91-7 98.13%
    Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban acetate
  • HY-103064
    2-Methylthio-AMP sodium 81921-45-1 98%
    2-Methylthio-AMP sodium is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP sodium is an inhibitor of ADP-dependent platelet aggregation.
    2-Methylthio-AMP sodium
  • HY-10307A
    Roxifiban acetate 176022-59-6 98%
    Roxifiban (acetate) is the acetate form of Roxifiban (HY-10307). Roxifiban (acetate) is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in research related to angina.
    Roxifiban acetate
  • HY-103114
    AT1015 hydrochloride 190508-50-0 98%
    AT1015 hydrochloride is a potent antagonist of 5-HT2 receptor, with the pKi of 7.94. AT1015 inhibits vasoconstriction and blocks platelet aggregation.
    AT1015 hydrochloride
  • HY-103116
    DV-7028 hydrochloride 133364-62-2 98%
    DV-7028 is a selective 5-hydroxytryptamine2 (5-HT2) receptor antagonist.
    DV-7028 hydrochloride
  • HY-10314A
    Lotrafiban hydrochloride 179599-82-7 98%
    Lotrafiban hydrochloride is an orally-active platelet GPIIb/IIIa blocker for research of coronary and cerebrovascular disease.
    Lotrafiban hydrochloride
  • HY-10315A
    Elarofiban diTFA 198958-89-3 98%
    Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research.
    Elarofiban diTFA
  • HY-103179
    SDZ-WAG994 130714-47-5 98%
    SDZ-WAG994 (WAG-994) is a stable, long-acting, selective and orally active A1-adenosine receptor agonist with a KD of 23 nM. SDZ-WAG994 can be used for the research of atrial fibrillation.
    SDZ-WAG994
  • HY-103202
    SNAP5089 hydrochloride 157066-77-8 98%
    SNAP5089 (hydrochloride) is a selective α1A adrenergic receptor antagonist. SNAP5089 (hydrochloride) can be used in the research of hypertension and benign prostatic hyperplasia.
    SNAP5089 hydrochloride
  • HY-103209
    Rec 15/2615 hydrochloride 173059-17-1 98%
    Rec 15/2615 hydrochloride is a potent and selective α-1B adrenoceptor antagonist with Ki values of 1.9 nM, 0.3 nM, 2.6 nM for α1A, α1B, α1D, respectively. Rec 15/2615 hydrochloride modulates vaginal smooth muscle contractility and genital engorgement.
    Rec 15/2615 hydrochloride
  • HY-103247
    EMD 66684 1216884-39-7 98%
    EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant -.
    EMD 66684
  • HY-103276
    Alytesin 31078-12-3 98%
    Alytesin, a bombesin-like peptide, is found in extracts of the skin of Alytes obstetricans. Alytesin reduces gastric acid secretion and induces hypertension. Alytesin also induces short-term anorexigenic effects in neonatal chicks
    Alytesin
  • HY-103292
    [Phe8Ψ(CH-NH)Arg9]-Bradykinin 118122-39-7 98%
    [Phe8Ψ(CH-NH)Arg9]-Bradykinin is a selective Bradykinin receptor B2 agonist (not cleaved by protein kinase I/II). [Phe8Ψ(CH-NH)Arg9]-Bradykinin has potential for the research of hypertension.
    [Phe8Ψ(CH-NH)Arg9]-Bradykinin
  • HY-103293
    Lys-Bradykinin 342-10-9 98%
    Lys-Bradykinin, a kind of kallidin and bradykinin receptor ligand, can be generated by kininogen protein through enzymatic cleavage by the protease kallikrein. Lys-Bradykinin, also a vasodilator, can widen blood vessels and increase blood flow. ys-Bradykinin stimulates net Na+ influx, and also the DNA synthesis. Lys-Bradykinin involves in vascular regulation, inflammation and pain sensation.
    Lys-Bradykinin
  • HY-103313
    SR33805 oxalate 121346-33-6 98%
    SR33805 oxalate is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 oxalate blocks L-type but not T-type Ca2+ channels. SR33805 oxalate can be used for the research of acute or chronic failing hearts.
    SR33805 oxalate
  • HY-103459
    CI-1020 162256-50-0 98%
    CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration.
    CI-1020
  • HY-103653
    CKD-731 251111-15-6 98%
    CKD-731 is a Fumagillin (HY-B0751) analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer.
    CKD-731
Cat. No. Product Name / Synonyms Application Reactivity